Summary of baseline characteristics of RCTs
| Study . | Griffin . | Cassiopeia∗ . | IsKia† . | GEM2017FIT‡ . | PERSEUS . | GMMG-HD7 . | IMROZ . |
|---|---|---|---|---|---|---|---|
| First author, y | Voorhees 202015 and 20235 | Moreau 201916 and 20214 | Gay 202314 | Mateos 202317 | Sonneveld 20246 | Goldschmidt 202218 | Facon 20249 |
| Phase | 2 | 3 | 3 | 3 | 3 | 3 | 3 |
| Sample size (intervention:control) | 104:103 | 543:542 | 151:151 | 153:154 | 355:354 | 331:329 | 265:181 |
| Median age (intervention:control) | 59:61 | 59:58 | 61:60 | NR | 59:60 | 61:59 | NR |
| Intervention | Dara-VRd | Dara-VTd | Isa-KRd | Dara-KRd | Dara-VRd | Isa-VRd | Isa-VRd |
| Control | VRd | VTd | KRd | KRd | VRd | VRd | VRd |
| HRMM definition | del 17p, t(4;14), t(14;16) | del 17p, t(4;14) | del 17p, t(4;14), t(14;16) | del 17p, t(4;14), t(14;16) | del 17p, t(4;14), t(14;16) | del 17p, t(4;14), t(14;16) | NR |
| HRMM participants, n (%), (intervention:control) | 16 (16):14 (14) | 82 (15):86 (16) | 27 (18):29 (19) | NR | 76 (21):78 (22) | 58 (18):66 (20) | NR |
| Median follow-up | 49.6 mo | 80.1 mo | 20 mo | NR | 47.5 mo | 125 d | 59.7 mo |
| Stem cell transplant intent | Yes | Yes | Yes | No | Yes | Yes | No |
| Maintenance regimen | Lenalidomide for all daratumumab added for the intervention arm only | Second randomization to daratumumab or observation | NA | No maintenance Control arm received 4 cycles DRd consolidation | Lenalidomide for all Daratumumab added for the intervention arm only | NA | NA |
| Study . | Griffin . | Cassiopeia∗ . | IsKia† . | GEM2017FIT‡ . | PERSEUS . | GMMG-HD7 . | IMROZ . |
|---|---|---|---|---|---|---|---|
| First author, y | Voorhees 202015 and 20235 | Moreau 201916 and 20214 | Gay 202314 | Mateos 202317 | Sonneveld 20246 | Goldschmidt 202218 | Facon 20249 |
| Phase | 2 | 3 | 3 | 3 | 3 | 3 | 3 |
| Sample size (intervention:control) | 104:103 | 543:542 | 151:151 | 153:154 | 355:354 | 331:329 | 265:181 |
| Median age (intervention:control) | 59:61 | 59:58 | 61:60 | NR | 59:60 | 61:59 | NR |
| Intervention | Dara-VRd | Dara-VTd | Isa-KRd | Dara-KRd | Dara-VRd | Isa-VRd | Isa-VRd |
| Control | VRd | VTd | KRd | KRd | VRd | VRd | VRd |
| HRMM definition | del 17p, t(4;14), t(14;16) | del 17p, t(4;14) | del 17p, t(4;14), t(14;16) | del 17p, t(4;14), t(14;16) | del 17p, t(4;14), t(14;16) | del 17p, t(4;14), t(14;16) | NR |
| HRMM participants, n (%), (intervention:control) | 16 (16):14 (14) | 82 (15):86 (16) | 27 (18):29 (19) | NR | 76 (21):78 (22) | 58 (18):66 (20) | NR |
| Median follow-up | 49.6 mo | 80.1 mo | 20 mo | NR | 47.5 mo | 125 d | 59.7 mo |
| Stem cell transplant intent | Yes | Yes | Yes | No | Yes | Yes | No |
| Maintenance regimen | Lenalidomide for all daratumumab added for the intervention arm only | Second randomization to daratumumab or observation | NA | No maintenance Control arm received 4 cycles DRd consolidation | Lenalidomide for all Daratumumab added for the intervention arm only | NA | NA |
Dara-KRd, Daratumumab with carfilzomib, lenalidomide, and dexamethasone; Dara-VRd, daratumumab with bortezomib, lenalidomide, and dexamethasone; DRd, daratumumab, lenalidomide, and dexamethasone; Isa-KRd, isatuximab with carfilzomib, lenalidomide, and dexamethasone; Isa-VRd, isatuximab with bortezomib, lenalidomide, and dexamethasone; KRd, carfilzomib, lenalidomide, and dexamethasone; NA, not applicable; NR, not reported; VRd, bortezomib, lenalidomide, and dexamethasone; VTd, bortezomib, thalidomide, and dexamethasone.
Cassiopeia 2021 included second randomization to maintenance daratumumab or observation but data included by induction regimen.
Abstract only.
‡Abstract only. Third arm with bortezomib, melphalan, and prednisone followed by lenalidomide excluded.